() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

PreveCeutical Files Application to Human Ethics Committee to
Acquire Human Tissue for the Final Phase of the Sol-Gel Program

April 15th, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces the Company’s research team at the University of Queensland has filed an application to a local hospital’s Human Ethics Committee (the “Human Ethics Committee”) to acquire human nasal mucosal tissue (mucosal membrane) for use in the final phase of the cannabinoid-based, soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”).


PreveCeutical has previously demonstrated effective delivery and retention of the Sol-gels to the olfactory epithelium in an adult human nasal cast using a custom applicator device (the “Sol-gel Applicator”) (see news release dated November 19, 2018).

PreveCeutical’s President and Chief Science Officer, Dr. Mak Jawadekar stated,

This is an important next step for the Sol-gel Program. Having demonstrated, in an in-vitro model, using an adult human nasal cast, that the Company’s CBD Sol-gel is delivered to and retained directly at target tissue high in the nasal cavity when administered with the Sol-gel Applicator, we look forward to testing the Sol-gels on human nasal tissue. This will allow PreveCeutical to potentially deliver a host of therapeutics safely from nose-to-brain in a reliable and sustained manner, which remains a significant challenge for many companies, globally

PreveCeutical believes that the outcomes of its Sol-gel Program may be of value to companies interested in delivering pharmaceuticals to the central nervous system (the “CNS”). Achieving patient benefit from the use of medicinal cannabis for the management of CNS conditions, such as epilepsy, anxiety and depression, may be a function of achieving effective and sustained delivery of the cannabis-based therapeutic to brain tissue. When taken orally, medicinal cannabis can cause gastrointestinal upset, and when absorbed across the gut it is broken down by enzymes. As common drug delivery methods do not provide effective and sustained delivery to the brain, the delivery of cannabinoids to the CNS is a universal problem.

Should the application to the Human Ethics Committee be granted, the final phase of the Sol-gel Program may begin.  During the final phase, the Company intends to study and report on the delivery of the cannabis-infused Sol-gels to freshly explanted nasal mucosal tissue.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

On Behalf of the Board of Directors

“Dr. Makarand (Mak) Jawadekar”
President & Chief Science Officer

For further information, please contact:

Deanna Kress
Director of Corporate Communications & Investor Relations

Comments are closed.